High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

This study is looking for children and young people who have been diagnosed with high-risk neuroblastoma, usually before they've started much treatment. This might include those with a widespread form of the cancer, or those with a specific genetic change in their cancer cells (called MYCN amplification).

If you've already started some chemotherapy, you might still be able to join, especially if it was a very early treatment for an emergency situation or for a more localized cancer. Generally, participants should be diagnosed with neuroblastoma according to specific international guidelines.

Girls and young women who might become pregnant will need to take a pregnancy test and agree to use effective contraception during the study and for a year afterwards.

Taking part in this study means you would follow a specific treatment plan that involves different types of chemotherapy and potentially radiotherapy. These treatments are given at specialist hospitals. You would have regular visits to the hospital for your treatments, check-ups, and tests to see how you are responding. The doctors will monitor you closely throughout the treatment period.

Because this study compares different treatment approaches, participants will be randomly chosen for one of several groups. This ensures a fair comparison. The total duration of your participation would involve the treatment period itself, followed by ongoing check-ups for several years to track your long-term health and the cancer's status.